{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"13.5","upperLimit":"17.3","value":"15.6"},{"groupId":"OG001","lowerLimit":"7.2","upperLimit":"14.8","value":"11.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"214"},{"groupId":"OG001","value":"108"}],"units":"Participants"}],"description":"Overall survival was defined as the time from the date of randomization to the date of death due to any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with histologically confirmed cutaneous advanced or metastatic melanoma (Stage IIIC or Stage IV), with a BRAF (a human gene encoding for protein called B-Raf, which is involved in a signaling pathway and is important for cell growth) V600 E/K mutation-positive tumor sample as determined via the central BRAF mutation assay, received a Trametinib 2 milligram (mg) tablet once daily until disease progression, death, or withdrawal.","id":"OG000","title":"Trametinib"},{"description":"Participants with histologically confirmed cutaneous advanced or metastatic melanoma (Stage IIIC or Stage IV), with a BRAF V600 E/K mutation-positive tumor sample as determined via the central BRAF mutation assay, received an intravenous (IV) dose of Dacarbazine 1000 mg per square meter every 3 weeks or Paclitaxel 175 mg per square meter every 3 weeks at the discretion of the investigator, provided the participant had not received that type of chemotherapy before randomization, until disease progression, death, or withdrawal.","id":"OG001","title":"Chemotherapy"}],"paramType":"MEDIAN","populationDescription":"ITT Population","reportingStatus":"POSTED","timeFrame":"Day 1 until death due to any cause (average of 20.3 months)","title":"Overall Survival in All Participants","type":"SECONDARY","unitOfMeasure":"Months"}